Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

William Tamborlane

Pediatric Endocrinology New Haven, CT Medical Doctor

NPI 1124001342 CMS profile 95762

2 Church St S, Suite 511, New Haven, CT 06519

Open in the dashboard

General payments

$181,841

91 records reported · program years 2019–2024

Research payments

$5,345

Paid to them · 7 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$931,471 paid to institutions, not to them · program years 2019–2025

Through program year 2024, William Tamborlane of New Haven, CT is reported in the CMS Open Payments database as having received $181,841 across 91 general payments and $5,345 in research payments paid to them. Separately, studies naming them as principal investigator received $931,471 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $857 2
2023 General $28,060 11
2022 General $24,276 5
2021 General $14,860 4
2020 General $44,744 13
2019 General $69,044 56
2019 Research $5,345 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Tamborlane
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to William Tamborlane were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year William Tamborlane Pediatric Endocrinology median Middle half National median
2019 $69,044 $196 $68–$845 $163
2020 $44,744 $124 $37–$722 $114
2021 $14,860 $134 $35–$691 $132
2022 $24,276 $177 $47–$726 $149
2023 $28,060 $236 $75–$887 $160
2024 $857 $259 $91–$979 $164
2025 $0 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $103,276 26 payments
  2. Medtronic MiniMed, Inc. $24,424 25 payments
  3. Novo Nordisk Inc $14,383 15 payments
  4. Novo Nordisk AS $10,813 3 payments
  5. Ipsen Bioscience Inc $9,000 1 payment
  6. Medtronic, Inc. $7,500 2 payments
  7. Boehringer Ingelheim International GmbH $5,943 10 payments
  8. Eisai Inc. $3,850 3 payments
  9. Sanofi-Aventis U.S. LLC $2,340 1 payment
  10. Companion Medical, Inc. $140 2 payments
  11. Other $172 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $146,105 30 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,093 14 payments
  3. Travel and Lodging $5,029 24 payments
  4. Food and Beverage $1,614 23 payments
Products named General payments · program years 2019–2024
  1. TRADJENTA $87,000 15 payments
  2. JARDIANCE Diabetes $21,317 18 payments
  3. Victoza $11,809 9 payments
  4. Minimed 670G System $10,084 18 payments
  5. Tresiba $6,537 5 payments
  6. Belviq $3,850 3 payments
  7. TOUJEO $2,340 1 payment
  8. JARDIANCE Diabetes $857 2 payments
  9. InPen $140 2 payments
  10. FASENRA $132 1 payment
  11. Other $87 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Sanofi-Aventis U.S. LLC $5,345 7 payments

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record